Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL2324976 | 1.00 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL28331087 | 0.96 | GSR (0.77) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL445453 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Ornithine Aketoglutarate SCHEMBL27686822 | 0.92 | GSR (0.69) | GSRARG2ARG1NOS2CYP1A2 | |
| Lysine SCHEMBL17102268 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL22534312 | 0.92 | GSR (0.83) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1645 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL456381 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL20362357 | 0.91 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118616094-A | Artificial enzyme with laccase-like catalytic activity, and preparation method and application thereof | 天津大学 | 2024-09-10 | — | — | CN | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| EP-0844890-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997006829-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | GSR 704/4885ARG2 176/4885ARG1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.